Mark Tykocinski

TitleVice Chn Prvst, Dean SKMC EVP,
InstitutionThomas Jefferson University
DepartmentSKMC - Senior Administration
Address1025 Walnut St.
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R29CA047566     (TYKOCINSKI, MARK L)May 1, 1988 - Apr 30, 1993
    NIH
    HUMAN LEUKEMIC DIFFERENTIATION--ANTI-SENSE RNA STUDIES
    Role: Principal Investigator

    R01AI031044     (TYKOCINSKI, MARK L)Jul 1, 1992 - May 31, 2008
    NIH
    Engineering Artifical Veto Cells
    Role: Principal Investigator

    R01AI038960     (TYKOCINSKI, MARK L)Feb 15, 1996 - Jan 31, 2006
    NIH
    PLACENTAL PROTEIN 14 AS A UNIQUE IMMUNOREGULATOR
    Role: Principal Investigator

    R01CA069646     (TYKOCINSKI, MARK L)Sep 16, 1996 - Jun 30, 2000
    NIH
    H19 IN BLADDER CANCER
    Role: Principal Investigator

    R01CA074958     (TYKOCINSKI, MARK L)Sep 1, 1997 - Jul 31, 2008
    NIH
    CELLULAR CANCER VACCINES
    Role: Principal Investigator

    R03TW006148     (TYKOCINSKI, MARK L)Dec 15, 2002 - Nov 30, 2005
    NIH
    Placental Protein 14 as a Lectin-Like Immunomodulator
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Makdasi E, Amsili S, Aronin A, Prigozhina TB, Tzdaka K, Gozlan YM, Ben Gigi-Tamir L, Sagiv JY, Shkedy F, Shani N, Tykocinski ML, Dranitzki Elhalel M. Toxicology and Pharmacokinetic Studies in Mice and Non-Human Primates of the Non-Toxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL. Mol Cancer Ther. 2019 Dec 23. PMID: 31871267.
      Citations:    
    2. Sanfilippo F, Powell D, Folberg R, Tykocinski M. Dealing With Deans and Academic Medical Center Leadership: Advice From Leaders. Acad Pathol. 2018 Jan-Dec; 5:2374289518765462. PMID: 29662949.
      Citations:    
    3. Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res. 2016 Jul; 14(7):599-611. PMID: 27053682.
      Citations:    
    4. Hojat M, Michalec B, Veloski JJ, Tykocinski ML. Can empathy, other personality attributes, and level of positive social influence in medical school identify potential leaders in medicine? Acad Med. 2015 Apr; 90(4):505-10. PMID: 25629944.
      Citations:    
    5. Michalec B, Veloski JJ, Hojat M, Tykocinski ML. Identifying potential engaging leaders within medical education: The role of positive influence on peers. Med Teach. 2014 Aug 26; 1-7. PMID: 25155553.
      Citations:    
    6. Aronin A, Amsili S, Prigozhina TB, Tzdaka K, Rachmilewitz J, Shani N, Tykocinski ML, Dranitzki Elhalel M. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth. PLoS One. 2013; 8(10):e77050. PMID: 24130833.
      Citations:    
    7. Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, Tanowitz HB, Sotgia F, Lisanti MP. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle. 2011 Dec 15; 10(24):4208-16. PMID: 22033146.
      Citations:    
    8. Orbach A, Rachmilewitz J, Shani N, Isenberg Y, Parnas M, Huang JH, Tykocinski ML, Dranitzki-Elhalel M. CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol. 2010 Dec; 177(6):3159-68. PMID: 21088216.
      Citations:    
    9. Ochanuna Z, Geiger-Maor A, Dembinsky-Vaknin A, Karussis D, Tykocinski ML, Rachmilewitz J. Inhibition of effector function but not T cell activation and increase in FoxP3 expression in T cells differentiated in the presence of PP14. PLoS One. 2010; 5(9):e12868. PMID: 20886106.
      Citations:    
    10. Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, Tykocinski ML. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol. 2009 Feb; 174(2):460-74. PMID: 19147815.
      Citations:    
    11. Razmara M, Hilliard B, Ziarani AK, Chen YH, Tykocinski ML. CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells. Int Immunol. 2008 Apr; 20(4):471-83. PMID: 18272926.
      Citations:    
    12. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008 Feb; 9(2):194-202. PMID: 18157133.
      Citations:    
    13. Orbach A, Rachmilewitz J, Parnas M, Huang JH, Tykocinski ML, Dranitzki-Elhalel M. CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol. 2007 Dec 1; 179(11):7287-94. PMID: 18025171.
      Citations:    
    14. Tone Y, Kojima Y, Furuuchi K, Brady M, Yashiro-Ohtani Y, Tykocinski ML, Tone M. OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol. 2007 Aug 1; 179(3):1760-7. PMID: 17641042.
      Citations:    
    15. Ish-Shalom E, Gargir A, André S, Borovsky Z, Ochanuna Z, Gabius HJ, Tykocinski ML, Rachmilewitz J. alpha2,6-Sialylation promotes binding of placental protein 14 via its Ca2+-dependent lectin activity: insights into differential effects on CD45RO and CD45RA T cells. Glycobiology. 2006 Mar; 16(3):173-83. PMID: 16269626.
      Citations:    
    16. Crawford JM, Tykocinski ML. Pathology as the enabler of human research. Lab Invest. 2005 Sep; 85(9):1058-64. PMID: 16056243.
      Citations:    
    17. Mishan-Eisenberg G, Borovsky Z, Weber MC, Gazit R, Tykocinski ML, Rachmilewitz J. Differential regulation of Th1/Th2 cytokine responses by placental protein 14. J Immunol. 2004 Nov 1; 173(9):5524-30. PMID: 15494501.
      Citations:    
    18. Skornicka EL, Kiyatkina N, Weber MC, Tykocinski ML, Koo PH. Pregnancy zone protein is a carrier and modulator of placental protein-14 in T-cell growth and cytokine production. Cell Immunol. 2004 Nov-Dec; 232(1-2):144-56. PMID: 15882859.
      Citations:    
    19. Elhalel MD, Huang JH, Schmidt W, Rachmilewitz J, Tykocinski ML. CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J Immunol. 2003 Jun 15; 170(12):5842-50. PMID: 12794109.
      Citations:    
    20. Chen A, Zheng G, Tykocinski ML. Quantitative interplay between activating and pro-apoptotic signals dictates T cell responses. Cell Immunol. 2003 Feb; 221(2):128-37. PMID: 12747954.
      Citations:    
    21. Rachmilewitz J, Borovsky Z, Riely GJ, Miller R, Tykocinski ML. Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45. J Biol Chem. 2003 Apr 18; 278(16):14059-65. PMID: 12556471.
      Citations:    
    22. Tykocinski ML, Chen A, Huang JH, Weber MC, Zheng G. New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints. Immunol Res. 2003; 27(2-3):565-74. PMID: 12857999.
      Citations:    
    23. Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, Geho DH, Tykocinski ML, Besra GS, Porcelli SA. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol. 2002 May; 3(5):435-42. PMID: 11938350.
      Citations:    
    24. Rachmilewitz J, Borovsky Z, Mishan-Eisenberg G, Yaniv E, Riely GJ, Tykocinski ML. Focal localization of placental protein 14 toward sites of TCR engagement. J Immunol. 2002 Mar 15; 168(6):2745-50. PMID: 11884441.
      Citations:    
    Tykocinski's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (154)
    Explore
    _
    Co-Authors (6)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _